Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itepekimab in non-cystic fibrosis bronchiectasis
NL-OMON60012Phase 2Completed
- Sponsor
- Sanofi
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in bronchiectasis comparing Itepekimab with Placebo (2 arms). Primary endpoint: Annualized rate of moderate or severe pulmonary exacerbations over the treatment period. Started Dec 2024; status: completed.
02
Drugs
itepekimab
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on NL-OMON60012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60012.